Filamentous fungi could produce at least 1.4 million unique compounds with therapeutic and industrial potential. Using a new tool called mGem, researchers analyzed over 1,100 fungal genomes and uncovered an average of 78 gene clusters per species for making bioactive secondary metabolites. That’s 18 times more than what’s currently cataloged. Many of these compounds have antifungal, antibacterial, or anticancer properties—marking fungi as a vastly untapped source for drug discovery, agriculture, and food innovation.